Bedrijfsoverzicht
Voyager Therapeutics, Inc. is a biotechnology enterprise dedicated to advancing the understanding of human genetics to develop curative therapies for neurological disorders. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, where it leverages gene therapy and antibody programs to address conditions such as Alzheimer's disease and tau-related pathologies. As of the latest reporting period, the firm maintains a market capitalization of $222.90M, generates annual revenue of $40.37M, and employs a workforce of 141 individuals. These financial dimensions indicate that Voyager Therapeutics functions as a mid-cap entity with a revenue base that supports its R&D-intensive operations but remains below the scale of large-cap pharmaceutical peers, reflecting the early-to-mid stage nature of its commercialization efforts in the specialized neurological disease market.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $40.37M alongside a net income loss of $119,721,000 and an EBITDA of $-124,284,000, highlighting a significant divergence between top-line generation and bottom-line profitability. This substantial gap between revenue and net income reveals a cost structure heavily weighted toward research and development expenditures and operating overhead that exceeds current sales revenue, a typical characteristic of pre-commercialization biotechnology firms. The free cash flow stands at $-83,939,000, indicating that the company is currently burning cash to fund its operations and pipeline advancement rather than generating internal liquidity. Despite the negative cash flow, Voyager Therapeutics holds $196.45M in cash against $36.50M in debt, providing a robust liquidity buffer that supports its financial flexibility for several years of development. The balance sheet appears conservative relative to its debt load, evidenced by a debt-to-equity ratio of 18.61, while the current ratio of 7.64 suggests strong short-term liquidity capabilities to cover obligations. However, the return metrics present a challenging picture for profitability analysis, with a return on equity of -48.3% and a return on assets of -24.9%, which reveal that management has not yet achieved positive returns on the capital base due to the ongoing investment phase. Furthermore, the gross margin of -227.6%, operating margin of -172.4%, and profit margin of -296.5% all reflect negative margins that are common in the biotech sector before products reach the market, yet they signal that operating costs are currently outpacing gross sales revenue.
Waarderingsbeoordeling
Valuation multiples for Voyager Therapeutics are presented in a manner that reflects its lack of current profitability, with a trailing P/E ratio of N/A and a forward P/E of -2.18. The discrepancy between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing the stock based on future expectations of earnings recovery rather than historical performance, suggesting that analysts anticipate a trajectory where losses may narrow or turn to profit as product milestones are achieved. The price-to-book ratio is recorded at 1.13, indicating that the market values the company at a slight premium over its tangible book value, which is relatively low for a biotech firm with significant intangible assets like intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 5.52 and the EV/EBITDA of -0.51 provide further insight, suggesting that investors are willing to pay a premium for sales growth potential despite the current lack of earnings generation. In terms of trading range, the stock has fluctuated between a 52-week high of $5.55 and a 52-week low of $2.65, and without a specific current price in the provided data, the valuation sits within this historical volatility band. The beta of 1.38 indicates that the stock's price volatility is significantly higher than the broader market, exposing shareholders to greater price swings that correlate with the high-risk profile of small-cap biotechnology investments.
Growth & Income
Voyager Therapeutics has demonstrated aggressive top-line expansion with a revenue growth year-over-year of 144.3%, whereas earnings growth is listed as N/A due to the company's continued net losses. The disparity between robust revenue growth and the absence of earnings growth implies that the company is successfully expanding its commercial footprint but has not yet translated these sales into net income, a standard phase for biotechnology companies scaling up before commercial product launches. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio stands at 0.0%, confirming that all available earnings are theoretically available for reinvestment, though currently, there are no earnings to distribute. Consequently, the company reinvests its resources entirely into research and development activities to advance its pipeline of tau silencing gene therapies and anti-tau antibody programs rather than returning capital to shareholders. The overall growth and income profile characterizes Voyager Therapeutics as a pure-play growth vehicle where value is derived from pipeline potential and revenue scaling rather than current cash distributions or established profitability.